Comparison of the Effects of Selective Endothelin ETaand ETbReceptor Antagonists in Congestive Heart Failure  by Wada, Atsuyuki et al.
EXPERIMENTAL STUDIES
Comparison of the Effects of Selective Endothelin ETA and ETB
Receptor Antagonists in Congestive Heart Failure
ATSUYUKI WADA, MD, TAKAYOSHI TSUTAMOTO, MD, DAISUKE FUKAI, MD,
MASATO OHNISHI, MD, KEIKO MAEDA, MD, TOMOKO HISANAGA, MD,
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Objectives. This study was designed 1) to determine the extent
to which endogenous endothelin (ET) affects hemodynamic, hor-
monal and body fluid balance through ETA and ETB receptors in
congestive heart failure (CHF); and 2) to assess the therapeutic
benefits and adverse effects of ET receptor antagonists for ETA
and ETB on cardiorenal and neurohormonal variables.
Background. ET has two receptors, ETA and ETB, both of which
are distributed in various tissues and cells. In vascular beds, ETA
receptors mediate vasoconstriction, whereas ETB receptors medi-
ate vasorelaxation. However, ETB receptors also exist in smooth
muscle and mediate vasoconstriction.
Methods. We administered either the ETA receptor antagonist
FR139317 (FR [n 5 8], 1 and 10 mg/kg body weight) or the ETB
receptor antagonist RES-701-1 (RES [n 5 8], 0.2 and 1.5 mg/kg)
to dogs with CHF induced by rapid ventricular pacing. The effects
of both antagonists on cardiorenal and hormonal functions were
studied.
Results. FR decreased cardiac pressures and the plasma atrial
natriuretic peptide (ANP) level and increased cardiac output
(CO). Urinary flow rate and urinary sodium excretion increased
in association with an increase in the glomerular filtration rate
and renal plasma flow (RPF). In contrast, RES increased cardiac
pressures and decreased CO. It also decreased the plasma aldo-
sterone level and RPF. Neither antagonist affected plasma nor-
epinephrine levels.
Conclusions. Endogenous ETs increase cardiac pressures and
the retention of body fluid through ETA receptors in CHF. The
vasodilative action through ETB receptors is overall functionally
more important than the constrictive action through ETB recep-
tors. ETs may regulate the secretion of ANP and aldosterone. Our
findings suggest that selective ETA receptor antagonists have
potential therapeutic benefits affecting both hemodynamic vari-
ables and diuresis, whereas ETB receptor antagonists have ad-
verse hemodynamic effects, with the possibility of preventing fluid
retention through suppression of aldosterone secretion in dogs
with CHF.
(J Am Coll Cardiol 1997;30:1385–92)
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Endothelin (ET)-1 has two isoforms, ET-2 and ET-3, that
constitute a family of structurally homologous peptides (1,2),
and these ETs can bind to two ET receptors, ETA and ETB
(3,4). In vascular beds, ETA receptors, which exist in vascular
smooth muscle cells, mediate vasoconstriction, whereas ETB
receptors, which predominantly exist in endothelial cells, me-
diate vasorelaxation through the release of nitric oxide and
prostacyclin (5). Not only does ET-1 have potent vasoconstric-
tor and pressor actions, it also decreases sodium and water
excretion and activates atrial natriuretic peptide (ANP) and
aldosterone secretion (6). In congestive heart failure (CHF),
the vasculature is generally constricted, body fluid is retained
and these humoral factors are activated. Therefore, ET-1 may
be involved in the pathogenesis of CHF. In fact, ET-1 circu-
lates in the plasma, and a significant elevation of the plasma
ET-1 level is observed in CHF compared with that in normal
control subjects (7,8). However, it can be difficult to assess the
pathophysiologic role of endogenous ETs because ETB recep-
tors also exist in the smooth muscle of some vascular beds and
mediate vasoconstriction (9). Some selective ETA and mixed
ETA/B receptor antagonists are now available, and both antag-
onists have beneficial effects on hemodynamic status (10,11).
Angiotensin-converting enzyme inhibitors not only can im-
prove hemodynamic status and lessen symptoms but also can
increase survival in CHF (12). If ET receptor antagonists have
a similar therapeutic potential for the treatment of CHF, it
could be useful to assess the interactions of ETs and other
neurohormones and the effects of ETs on body fluid balance in
an intact animal model. However, it is still not clear which of
these ET receptor blockades has the most therapeutic value for
the treatment of CHF, since there has been no comparison of
the effects mediated by ETA and ETB receptors both on
hemodynamic variables and on neurohormonal factors and
renal functions. Potent, competitive and highly selective antag-
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onists for ET receptors have been identified (13,14): FR139317
(FR) for ETA receptors, and RES-701-1 (RES) for ETB
receptors. In the present study, we investigated the extent to
which endogenous ETs affect hemodynamic, hormonal and
renal variables through each of the ET receptors using FR and
RES in dogs with CHF induced by right ventricular rapid
pacing. We also assessed the therapeutic benefits and adverse
effects of these ET antagonists on cardiorenal and neurohor-
monal functions.
Methods
Animal preparation. Conditioned male or female beagles,
weighing 10 to 13 kg, were used for all of the experiments, as
previously described (15). This study was approved by the
Animal Research Committee of Shiga University of Medical
Science. After anesthesia was induced with pentobarbital
sodium (25 mg/kg body weight), the dogs were ventilated.
Through a left thoracotomy, the heart was exposed, and two
cardiac pacemaker leads (Matsuda M-23) were sutured onto
the right ventricular apex. After the incision was closed, the
leads were tunneled to the back and connected to an external
pacemaker (Seamed 540). The left femoral vein was then
exposed, and a thermodilution catheter (Goodtec T-047-03)
was advanced into the pulmonary artery to measure right atrial
pressure, mean pulmonary artery pressure, pulmonary capil-
lary wedge pressure (PCWP) and cardiac output (CO). A
Tygon catheter (Norton R3603) was placed in the descending
thoracic aorta by way of the left femoral artery to measure
mean arterial pressure (MAP). The right jugular vein was also
catheterized, and the Tygon catheter was advanced into the
vena cava for drug administration. The central filling pressure
was recorded on a polygraph (Nihon Kohden RM-6000). CO
was assessed in triplicate by the thermodilution technique with
a Gould CO computer (Statham SP1435). Systemic vascular
resistance was calculated as [(MAP 2 right atrial pressure) 3
80]/CO, and pulmonary vascular resistance as [(mean pulmo-
nary arterial pressure 2 PCWP) 3 80]/CO. The dogs were
allowed to recover from the surgical procedure for at least 14
days before control study measurements and study 1 were
performed. After control hemodynamic and venous plasma
samples for neurohumoral determinations were obtained, the
pacemaker was programmed to an asynchronous mode at a
rate of 270 beats/min and pacing continued for 10 days for
study 2. Blood was drawn from the pulmonary artery through
the thermodilution catheter and transferred to specially pre-
pared tubes stored on ice to analyze plasma ET-1 and ANP,
aldosterone and norepinephrine concentrations. The blood
specimens were centrifuged at 4°C and the plasma was frozen
at 230°C until assay. All subsequent studies were performed
with animals in the conscious state.
Experimental protocol. Study 1: inhibitory effects of FR and
RES in response to ET-1. The selective nature of FR and RES
have been well demonstrated. FR (Fujisawa Pharmaceutical
Co., Ltd), showed a high affinity for ETA receptors on displace-
ment analysis using transfected Chinese hamster cells (16),
and it inhibited the constrictive effects of ET-1 in isolated
rabbit aorta (13). RES (Kyowa Hakko Kogyo Co., Ltd)
blocked the binding of ET-1 to bovine cerebellum, in which
ETB receptors are predominant (14), and inhibited ET-3–
induced endothelium-dependent relaxation in isolated rat
aorta (17).
To confirm the in vivo effects of FR and RES as ETA and
ETB receptor antagonists, we observed the inhibitory effects of
these antagonists on the responses of MAP, CO and systemic
vascular resistance to exogenously administered human ET-1
(Peptide Institute, Japan). Twelve dogs were randomly se-
lected and studied when they had completely recovered from
the effects of surgery. After the hemodynamic status had
stabilized, ET-1 (0.75 nmol/kg, n 5 4) was injected as a bolus.
FR (1 mg/kg, n 5 4) or RES (0.2 mg/kg, n 5 4) was
administered 5 min before ET-1 injection. The change in MAP
was recorded for 30 min in each group. CO was measured
before and 30 min after ET-1 injection and systemic vascular
resistance was calculated.
Study 2: cardiorenal and hormonal effects of FR and RES in
dogs with CHF. To evaluate the effects of endogenous ETs
mediated by ETA and ETB receptors in CHF, we separated the
dogs into three groups: The FR group (n 5 8) was given FR,
the RES group (n 5 8) was given RES and the vehicle group
(n 5 5) received only saline solution as a control. All subse-
quent measurements were recorded with ongoing rapid ven-
tricular pacing. As previously reported, the urinary bladder was
catheterized with a CLINY balloon tube (Create Medic Co.)
under brief thiopental sodium anesthesia (4 mg/kg), and
45 min later a priming dose of creatinine (50 mg/kg) and
para-aminohippurate (8 mg/kg) dissolved in 10 ml of saline
solution was infused over a period of 10 min (15). This infusion
was followed by a constant infusion (0.75 ml/min) of creatinine
(1.0 mg/kg per min) and para-aminohippurate (0.3 mg/kg per
min) throughout the experimental period. After a 60-min
equilibration period, the first of two clearance periods was
performed, each of which lasted for 20 min. After two sequen-
tial baseline periods, in the FR group, the first bolus dose of
FR at 1 mg/kg was administered intravenously. After 30 min,
the second dose of 10 mg/kg was injected, and two 30-min
clearances were performed for each dose. In the RES group,
RES was administered at 0.2 and 1.5 mg/kg at intervals of
Abbreviations and Acronyms
ANP 5 atrial natriuretic peptide
CHF 5 congestive heart failure
CO 5 cardiac output
ET 5 endothelin
FR 5 FR139317
GFR 5 glomerular filtration rate
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RPF 5 renal plasma flow
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30 min in the same way. In the vehicle group, saline solution
was administered at intervals of 30 min to exclude any tempo-
ral effects. During each clearance period, the cardiac pressure
data were recorded every 5 min, and CO and blood sampling
were performed at the end of each period.
Analysis of blood and urine samples. The plasma ET-1
concentration was determined by radioimmunoassay as previ-
ously described (18). Blood for aldosterone and ANP assay
was measured by radioimmunoassay as previously de-
scribed (15,19). Plasma norepinephrine concentration was
performed by high performance liquid chromatography as
previously reported (15). Serum and urinary creatinine, para-
aminohippurate and sodium concentrations were measured as
previously reported (15). Creatinine clearance and para-
aminohippurate clearance were calculated by using standard
formulas, and were equated with glomerular filtration rate
(GFR) and renal plasma flow (RPF), respectively. Filtration
fraction was calculated as GFR/RPF. Fractional excretion of
sodium was calculated by the standard formula.
Statistical analysis. All data are presented as mean
value 6 SEM. Analysis of variance for repeated measurements
was used to determine the significance of changes during
multiple time-dependent observations. Comparisons with
baseline values were analyzed by Dunnett’s test after analysis
of variance for repeated measurements. The Student t test was
used to analyze the significance of single comparisons. A p
value , 0.05 was considered significant.
Results
Blocking effects of FR and RES on ET-1 injection. The
effects of FR and RES on ET-1–induced changes are shown in
Figure 1, A to D. ET-1 produced an initial transient reduction
in MAP followed by a sustained increase in MAP that was
maximal within 18 min of injection. Corresponding to changes
in elevated MAP, systemic vascular resistance increased and
CO decreased. Pretreatment with FR significantly blocked
ET-1–induced hypertension for about 30 min after ET-1
injection and inhibited the reduction in CO and elevation of
systemic vascular resistance compared with values obtained
with ET-1 administration alone. In contrast, RES significantly
inhibited the initial transient reduction in MAP and aug-
mented the reduction in CO and the significant elevation of
systemic vascular resistance.
Characteristics of CHF. Baseline hemodynamic and endo-
crine characteristics of CHF induced by rapid right ventricular
pacing are summarized in Table 1 and Figure 2. In the FR,
RES and vehicle groups, PCWP was significantly increased but
MAP and CO were decreased relative to the respective baseline
values. Although right atrial pressure was increased, these
changes were not significant. Individual plasma ET-1 levels
were significantly increased compared with those in normal
control dogs, even though there was heterogeneity in this
model (Fig. 2). Plasma ANP, aldosterone and norepinephrine
concentrations were significantly increased in all three groups.
In addition to the deteriorated hemodynamic status and the
Figure 1. Graph showing the effects of FR (open circles,
n 5 4) and RES (open squares, n 5 4) on changes in
MAP (panels A and B), CO (panel C) and systemic
vascular resistance (SVR, panel D) induced by ET-1
(ET, open triangles, n 5 4) in dogs without CHF. FR
(1 mg/kg body weight) and RES (0.2 mg/kg) were
administered intravenously 5 min before intravenous ET
(0.75 nmol/kg) administration. #p , 0.05, †p , 0.01,
*p , 0.001 compared with values in ET group.
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activated hormonal secretion, CHF was considered present in
all of the dogs on the basis of evidence of anorexia and signs of
exertional dyspnea. When the hemodynamic and hormonal
baseline data of all experimental animals were pooled, the
differences among the three groups were not significant.
Hemodynamic effects of FR and RES. The hemodynamic
responses to the two incremental doses of FR or RES were
compared (Fig. 3, A to F). FR dose-dependently decreased
MAP and PCWP in association with significant reductions in
systemic and pulmonary vascular resistance. FR significantly
increased CO. However, RES caused significant elevation of
MAP, PCWP and systemic and pulmonary vascular resistance.
RES significantly decreased CO. Neither antagonist affected
right atrial pressure. Control saline injection did not affect
these hemodynamic variables.
Hormonal effects of FR and RES. The hormonal responses
to FR and RES are shown in Figure 4, A to D. FR did not
change plasma ET-1 levels, but RES significantly increased the
concentrations of ET-1. FR significantly decreased plasma
ANP levels, but RES did not alter ANP levels, despite
significant elevation of PCWP. RES significantly decreased
plasma aldosterone levels, but FR did not affect them. FR
tended to increase, whereas RES slightly reduced plasma
norepinephrine levels, but these changes were not significant.
None of these variables changed significantly in the vehicle
group.
Renal effects of FR and RES. The effects of FR and RES
on renal functions are shown in Table 2. FR significantly
increased the urinary flow rate and absolute urinary sodium
excretion over average basal values. FR also significantly
increased GFR and RPF, but it did not affect fractional sodium
excretion or filtration fraction. However, RES significantly
decreased RPF and increased the urinary flow rate. RES
tended to reduce urinary sodium excretion and GFR, but these
changes were not significant. RES significantly increased fil-
tration fraction but did not affect fractional sodium excretion.
There were no significant changes in the vehicle only group.
Discussion
The present study shows that FR, an ETA receptor antag-
onist, significantly reduced blood pressures and plasma ANP
level and increased CO. FR also increased the urinary flow rate
and sodium excretion associated with increasing GFR and
RPF. In contrast, RES, an ETB receptor antagonist, elevated
cardiac pressures and decreased CO. RES also decreased the
plasma aldosterone level and RPF. Neither antagonist affected
plasma norepinephrine levels. These results suggest that en-
dogenous ETs increase vascular resistance and retain body
fluids to maintain tissue perfusion through ETA receptors in
CHF. The vasodilative action through ETB receptors is overall
functionally more important than the constrictive action
through ETB receptors. The secretion of ANP and aldosterone
is regulated by endogenous ETs to modulate the vascular tone
and body fluid balance in CHF.
In study 1, pretreatment with FR did not show any inhibi-
tory effect on the initial transient depressor response to ET-1,
but it inhibited the subsequent pressor response. In contrast,
Table 1. Baseline Hemodynamic and Hormonal Characteristics of the 21 Study Dogs
FR Group (n 5 8) RES Group (n 5 8) Vehicle Group (n 5 5)
Baseline CHF Baseline CHF Baseline CHF
MAP (mm Hg) 121.5 6 6.9 97.3 6 2.3† 128.4 6 3.7 105.4 6 3.9† 116.6 6 2.4 98.2 6 3.0†
PCWP (mm Hg) 6.3 6 1.1 14.9 6 1.7‡ 3.8 6 0.7 13.0 6 1.0‡ 5.0 6 1.1 14.2 6 1.4‡
CO (liters/min) 2.52 6 0.19 1.56 6 0.14† 2.69 6 0.17 1.64 6 0.13‡ 2.91 6 0.28 1.52 6 0.17†
RAP (mm Hg) 2.8 6 0.3 4.3 6 0.6 1.9 6 0.3 3.1 6 0.7 2.6 6 0.7 4.4 6 0.4
ET-1 (pg/ml) 2.64 6 0.31 5.58 6 0.50† 3.02 6 0.19 5.72 6 1.17* 2.18 6 0.30 5.48 6 1.02*
ANP (pg/ml) 59 6 11 394 6 59‡ 44 6 3 314 6 35‡ 68 6 5 378 6 38‡
Aldo (pg/ml) 72 6 7 202 6 55* 76 6 9 192 6 50† 52 6 14 222 6 53*
NE (pg/ml) 233 6 29 531 6 136* 327 6 67 586 6 68* 249 6 57 532 6 88*
*p , 0.05, †p , 0.01, ‡p , 0.001 versus baseline. Values presented are mean value 6 SEM. Aldo 5 aldosterone; ANP 5 atrial natriuretic peptide; CHF 5
congestive heart failure; CO 5 cardiac output; ET-1 5 endothelin-1; FR 5 FR139317; MAP 5 mean arterial pressure; NE 5 norepinephrine; PCWP 5 pulmonary
capillary wedge presure; RAP 5 right atrial pressure; RES 5 RES-701-1; Vehicle 5 saline solution vehicle.
Figure 2. Changes in individual plasma endothelin-1 concentrations in
21 dogs: 8 FR139317-treated, 8 RES-701-1–treated and 5 given saline
vehicle alone before and after induction of congestive heart failure
(CHF). #p , 0.05, †p , 0.01 compared with baseline values.
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RES blunted the initial hypotension and augmented the in-
crease in systemic vascular resistance and decrease in CO
observed with ET-1 administration alone. Because the initial
transient depressor response has been reported (5) to be
mediated by ETB receptors, mainly through the release of
relaxing factors from vascular endothelium, the inhibition of
the initial depressor response must be the result of selective
antagonism of ETB receptors in vivo. As ETs act through
autocrine and paracrine mechanisms at local targets, plasma
ET-1 concentrations do not precisely reflect true ET activity
and there is no adequate index in intact animals for ET activity.
We considered the most overt index to be hemodynamic
changes, and we administered antagonists at doses that signif-
icantly affected blood pressure. FR and RES sufficiently inhib-
ited the effects of the pharmacologic dose of ET-1 in vivo.
Therefore, both antagonists were suitable for examining the
effects mediated by each ET receptor in CHF.
Hemodynamic changes. It is well known that ETA recep-
tors mediate vasoconstriction, whereas ETB receptors mediate
vasodilation through the release of nitric oxide and prostacy-
clin (5). However, because ETA and ETB receptors exist in
vascular smooth muscle cells and both receptors are involved
in the pressor response (9), the extent to which endogenous
ETs actually contribute to the regulation of blood pressures
through each receptor type has not yet been clarified in CHF.
In the present study, FR reduced MAP in association with a
decrease in systemic vascular resistance and increased CO,
whereas RES impaired hemodynamic status. Although a mixed
ETA/B receptor antagonist lowers blood pressure (11), there
has been no report that the systemic administration of a
selective ETB receptor antagonist induces vasoconstriction but
not vasodilation in CHF. Our results indicate that ETA recep-
tors exert a pathophysiologic vasoconstrictive effect and that
ETB receptors generally mediate vasodilative action rather
than vasoconstriction in CHF. A selective ETA antagonist may
have a beneficial hemodynamic effect and the blockade of ETB
receptors may produce hemodynamic deterioration by inhibit-
ing vasodilative actions. Although ET-1 has a positive inotropic
effect on cardiac muscle (20), the potent coronary vasocon-
strictive effect of ET-1 caused myocardial ischemia resulting in
Figure 3. Changes in MAP (A), PCWP (B),
RAP (C), CO (D), SVR (E) and PVR (F) in 21
dogs with CHF: 8 treated with FR139317 (FR,
open circles), 8 treated with RES-701-1 (RES,
open squares) and 5 receiving vehicle alone
(open triangles). Two bolus doses of FR (1 and
10 mg/kg) or RES (0.2 and 1.5 mg/kg) and
saline vehicle were given at intervals of 30 min.
#p , 0.05, †p , 0.01, *p , 0.001 compared
with baseline values. L 5 liters.
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decreased CO (6,7). FR might elicit a negative inotropic effect
(10), but this effect was overcome by the marked reduction of
vascular resistance.
Changes in plasma hormones. As for changes in plasma
ET-1 levels in response to ET antagonists, RES led to a
twofold increase in plasma ET-1 levels, whereas FR did not
significantly change plasma ET-1 levels. It was reported (21)
that intravenous ET-1 in rats was trapped by lungs, kidneys and
liver and that the retention of ET-1 was markedly reduced by
an ETB receptor but not by an ETA receptor antagonist. The
secretion of ET-1 into the cultured human endothelial cells
was enhanced by an ETB receptor antagonist without activating
preproET-1 messenger ribonucleic acid (mRNA) synthesis
(22). These results suggest that the increased ET-1 may be
displaced from ETB receptors of the endothelial cell layers or
that ETB receptors may mediate the clearance of ET-1 in
plasma.
ANP is a potent vasodilator and has effects opposite to
Figure 4. Bar graph showing the hormonal effects of FR139317 (FR
[solid bars, n 5 8]) and RES-701-1 (RES [open bars, n 5 8]) and
saline vehicle (hatched bars, n 5 5) on plasma endothelin-1 (A), ANP
(B), aldosterone (C) and norepinephrine concentrations (D) in dogs
with CHF. Two bolus doses of FR (1 and 10 mg/kg) or RES (0.2 and
1.5 mg/kg) and saline vehicle were given at intervals of 30 min. #p ,
0.05, †p , 0.01 compared with baseline values.
Table 2. Comparison of ETA and ETB Receptor–Mediated Renal Functions in Dogs With Heart Failure*
FR139317 (n 5 8) RES-701-1 (n 5 8) Saline Vehicle (n 5 5)
Baseline 1 mg/kg 10 mg/kg Baseline 0.2 mg/kg 1.5 mg/kg Baseline
Clearance
Period 1
Clearance
Period 2
U-V (ml/min) 0.84 6 0.08 1.02 6 0.16 1.10 6 0.13† 0.66 6 0.12 0.83 6 0.14 1.13 6 0.26† 0.62 6 0.08 0.68 6 0.15 0.72 6 0.12
U-Na (mEq/min) 29.7 6 10.9 54.8 6 24.8 75.9 6 27.4† 33.0 6 12.2 31.9 6 10.4 25.0 6 9.9 26.6 6 12.8 29.0 6 13.3 33.1 6 15.6
FE-Na 0.67 6 0.23 0.85 6 0.44 1.10 6 0.53 0.47 6 0.12 0.60 6 0.15 0.47 6 0.13 0.64 6 0.29 0.61 6 0.24 0.57 6 0.25
GFR (ml/min) 31.0 6 3.7 43.8 6 5.4† 45.3 6 3.9‡ 37.9 6 6.7 34.6 6 5.5 33.8 6 5.8 33.6 6 7.9 32.8 6 8.6 35.7 6 8.2
RPF (ml/min) 130.9 6 16.9 175.1 6 20.3 186.0 6 14.5† 135.7 6 26.1 121.4 6 22.4 86.3 6 16.9† 110.2 6 7.6 106.5 6 11.8 103.0 6 10.0
FF 0.24 6 0.01 0.25 6 0.02 0.25 6 0.02 0.31 6 0.03 0.30 6 0.02 0.40 6 0.03† 0.30 6 0.06 0.30 6 0.08 0.33 6 0.06
*After two 20-min basal clearance periods, FR139317 (1 and 10 mg/kg) or RES-701-1 (0.2 and 1.5 mg/kg) and saline vehicle were administered at 30-min intervals.
Two 30-min clearances were performed after the administration of each dose. Baseline values are the average obtained during the preceding basal period. †p , 0.05,
‡p , 0.01 versus baseline. Values presented are mean value 6 SEM. FE-Na 5 fractional excretion of sodium; FF 5 filtration fraction; GFR 5 glomerular filtration
rate; RPF 5 renal plasma flow; U-Na 5 urinary sodium excretion; U-V 5 urinary flow rate.
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those of ET-1. We (18) previously reported that endogenous
ANP inhibited the secretion of ET-1 through a cyclic
guanosine monophosphate (cGMP) pathway using an ANP
receptor antagonist. In rat atrial myocytes, an ETA receptor
antagonist, BQ-123, dose-dependently blocked ET-stimulated
ANP secretion, whereas an ETB receptor agonist, IRL-1620,
had no effect (23). In vitro, ET-1 may directly stimulate ANP
secretion through ETA receptors. However, in the present
study, the reduction in ANP with FR may reflect hemodynamic
improvement, expressed as a lowering of PCWP. Because ANP
is secreted in proportion to the severity of CHF and is a marker
for the prognosis of patients with CHF (24), the decline in
ANP levels with FR may indicate that an ETA receptor
antagonist can attenuate the aggravation of CHF.
ET-1 directly stimulates aldosterone secretion in the adre-
nal zona glomerulosa (25), and the administration of ET-1
increases the plasma aldosterone concentration in dogs (6,7).
Recently Belloni et al. (26) demonstrated that ET-1 enhanced
aldosterone secretion in dispersed zona glomerulosa cells, and
an ETB antagonist, but not an ETA antagonist, markedly
reduced this secretory response. As our findings are consistent
with these previous results, endogenous ETs may regulate
aldosterone secretion through ETB receptors in CHF.
Changes in renal function. In vitro, ET-1 has direct di-
uretic and natriuretic actions that inhibit Na1-K1 adenosine
triphosphatase activity (27) and reduce antidiuretic hormone–
stimulated water permeability in collecting ducts and results in
the excretion of hypotonic urine (28). However, the systemic
administration of ET-1 caused a profound increase in renal
vascular resistance and a reduction in urinary and sodium
excretion, associated with a significant decrease in RPF and
GFR (6,29). The roles of endogenous ETs in the kidney seem
to be very complex. In the present study, the increase in urinary
and sodium excretion induced by FR appear to be the conse-
quence of increased GFR and RPF. However, RES increased
urinary excretion despite reducing RPF. The exact mechanism
of these effects is unclear, and further investigation is needed.
As RES increased filtration fraction, RES might produce a
proportionally greater vasoconstriction in efferent rather than
afferent arterioles and increase the pressure within the down-
stream glomerular capillary (29). Elevation of the net filtration
pressure might overcome the decrease in RPF and preserve
GFR after RES administration and increase rather than
decrease the urinary flow rate (30). In fact, administration of
an NO synthase inhibitor and a prostaglandin inhibitor ele-
vated MAP and increased the urinary flow rate despite de-
creasing RPF (31,32). Therefore, we consider that the increase
in urinary flow produced by RES is a transient effect and the
long-term inhibition of ETB receptors decreases RPF and
results in decreased urinary excretion. Although Brooks et al.
(33) reported that the ETB receptor may inhibit sodium
reabsorption in a normal canine model, RES did not affect
absolute or fractional sodium excretion in the present study.
The direct tubular effects of endogenous ETs seemed to be
slight in CHF.
Limitations of the study. Because the development of
tachycardia-induced CHF is reversible and the termination of
rapid pacing results in improved cardiac and hormonal func-
tions (34), we performed these experiments with ongoing rapid
pacing even though it is very important to assess the effects of the
antagonists on changes in heart rate. Furthermore, it is possible
that a selective ET receptor antagonist blocking effects mediated
by one receptor may simultaneously augment the effects
mediated by the other receptor. Therefore, the observed
effects of ET antagonists may be in part the result of endoge-
nous ETs acting to stimulate the other ET receptor. However,
we could not accurately distinguish direct inhibitory effects from
actions augmented through other ET receptors in our study.
Conclusions. For the treatment of CHF, a selective ETA
receptor antagonist may offer therapeutic benefits improving
for both hemodynamic status and diuresis, whereas the inhibi-
tion of ETB receptors may have adverse effects on cardiac and
renal hemodynamics. However, it is possible that long-term
administration of ETB blockers may prevent volume retention
through the inhibition of aldosterone secretion in dogs with
CHF.
We thank Ikuko Sakaguchi for excellent technical assistance.
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